Hepatitis C drugs shown to boost remdesivir’s activity against SARS-CoV-2
Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
List view / Grid view
Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
A candidate vaccine has shown potential against MERS in non-human primates, when administered intradermally.
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
The drug MK-4482 decreased viral levels in the lungs of hamsters treated for SARS-CoV-2 infection, researchers have shown.
A study has shown that treatments to reduce levels of hydrogen sulphide (H2S) in the brain may help to prevent dementia.
A team has demonstrated in mouse models that a self-assembling nanofibre material could limit the damage caused by cytokines in inflammatory diseases.
Scientists have visualised the spatial and temporal distribution of neural stem cell activation in zebrafish models.
Researchers have shown that an mRNA delivery system can be used to produce the BDNF protein in rats to protect neurons from ischemia.
Studying the mouse gene Ophn1, researchers have found its removal causes stressed behaviours, also identifying three ways to reverse this effect.
Researchers have shown that miR-29 can control brain maturation in mammals, presenting a target for autism, epilepsy and other conditions.
A new VLP-based Zika virus vaccine is able to protect mice completely from infection, researchers have found.
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.